ASCO 2023: Osimertinib Reduces Mortality Risk in Early-Stage, Resected EGFR-Mutated NSCLC
Patients receiving osimertinib had a 51 percent lower risk for death compared with those receiving placebo
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.